PT2570128T - Antagonistas do receptor muscarínico de acetilcolina - Google Patents

Antagonistas do receptor muscarínico de acetilcolina

Info

Publication number
PT2570128T
PT2570128T PT121704027T PT12170402T PT2570128T PT 2570128 T PT2570128 T PT 2570128T PT 121704027 T PT121704027 T PT 121704027T PT 12170402 T PT12170402 T PT 12170402T PT 2570128 T PT2570128 T PT 2570128T
Authority
PT
Portugal
Prior art keywords
acetylcolin
antagonists
muscle receptor
muscle
receptor
Prior art date
Application number
PT121704027T
Other languages
English (en)
Portuguese (pt)
Inventor
Ibrahim Laine Dramane
R Palovich Michael
W Mcceland Brent
E Neipp Christopher
M Thomas Sonia
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2570128(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT2570128T publication Critical patent/PT2570128T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
PT121704027T 2004-04-27 2005-04-27 Antagonistas do receptor muscarínico de acetilcolina PT2570128T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Publications (1)

Publication Number Publication Date
PT2570128T true PT2570128T (pt) 2016-10-07

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
PT121704027T PT2570128T (pt) 2004-04-27 2005-04-27 Antagonistas do receptor muscarínico de acetilcolina
PT05746609T PT1740177E (pt) 2004-04-27 2005-04-27 Antagonistas do receptor muscarínico de acetilcolina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT05746609T PT1740177E (pt) 2004-04-27 2005-04-27 Antagonistas do receptor muscarínico de acetilcolina

Country Status (38)

Country Link
US (9) US7498440B2 (cg-RX-API-DMAC10.html)
EP (3) EP1740177B1 (cg-RX-API-DMAC10.html)
JP (2) JP5014121B2 (cg-RX-API-DMAC10.html)
KR (2) KR101037026B1 (cg-RX-API-DMAC10.html)
CN (2) CN1976701A (cg-RX-API-DMAC10.html)
AP (1) AP2213A (cg-RX-API-DMAC10.html)
AR (1) AR050902A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005237576B2 (cg-RX-API-DMAC10.html)
BE (1) BE2014C063I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0510170B8 (cg-RX-API-DMAC10.html)
CA (2) CA2755954C (cg-RX-API-DMAC10.html)
CY (3) CY1113196T1 (cg-RX-API-DMAC10.html)
DK (2) DK2570128T3 (cg-RX-API-DMAC10.html)
EA (2) EA021994B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP066940A (cg-RX-API-DMAC10.html)
ES (2) ES2600405T3 (cg-RX-API-DMAC10.html)
FR (1) FR14C0075I2 (cg-RX-API-DMAC10.html)
HR (2) HRP20120832T1 (cg-RX-API-DMAC10.html)
HU (2) HUE031304T2 (cg-RX-API-DMAC10.html)
IL (1) IL178152A (cg-RX-API-DMAC10.html)
LT (1) LT2570128T (cg-RX-API-DMAC10.html)
LU (1) LU92565I2 (cg-RX-API-DMAC10.html)
MA (1) MA28631B1 (cg-RX-API-DMAC10.html)
MX (1) MXPA06012405A (cg-RX-API-DMAC10.html)
MY (1) MY144753A (cg-RX-API-DMAC10.html)
NL (1) NL300694I1 (cg-RX-API-DMAC10.html)
NO (3) NO338959B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549997A (cg-RX-API-DMAC10.html)
PE (1) PE20060259A1 (cg-RX-API-DMAC10.html)
PL (2) PL2570128T3 (cg-RX-API-DMAC10.html)
PT (2) PT2570128T (cg-RX-API-DMAC10.html)
SG (1) SG186597A1 (cg-RX-API-DMAC10.html)
SI (2) SI2570128T1 (cg-RX-API-DMAC10.html)
TW (1) TWI363759B (cg-RX-API-DMAC10.html)
UA (1) UA95768C2 (cg-RX-API-DMAC10.html)
UY (1) UY28871A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005104745A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200608565B (cg-RX-API-DMAC10.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
MXPA06004242A (es) * 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
US20080194619A1 (en) * 2004-04-05 2008-08-14 Laurent Lecanu Anti-Hiv Quinuclidine Compounds
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
JP2008520579A (ja) * 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
ES2655083T3 (es) * 2010-01-28 2018-02-16 Theron Pharmaceuticals, Inc. Derivados de 7-azoniabiciclo [2.2.1]heptano, métodos de producción, y usos farmacéuticos de estos
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
CA2803418A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AU2012266541A1 (en) * 2011-06-08 2014-01-09 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
WO2012168160A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
JP6389174B2 (ja) * 2012-08-15 2018-09-12 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 化学的方法
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
HK1225317A1 (zh) 2013-07-30 2017-09-08 Glaxosmithkline Intellectual Property Development Limited 用於治疗过度出汗的局部组合物及其使用方法
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
US10987363B2 (en) 2014-05-28 2021-04-27 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of COPD
EP3215489B1 (en) 2014-11-03 2019-07-24 OLON S.p.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
MX384539B (es) * 2016-01-08 2025-03-14 Theron Pharmaceuticals Inc Composiciones de inhalador de polvo seco de derivados de 7-azoniabiciclo[2.2.1]heptano
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) * 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (cg-RX-API-DMAC10.html) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (en) * 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
SI1353919T1 (sl) * 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
RU2004110717A (ru) * 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
JP2005510523A (ja) * 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
CA2470956C (en) * 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20050711A1 (es) 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20050327A1 (es) 2003-07-17 2005-06-08 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
CN101230061A (zh) 2003-10-14 2008-07-30 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
MXPA06004242A (es) 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
PE20050861A1 (es) 2003-12-03 2005-12-10 Glaxo Group Ltd Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005086873A2 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20070185088A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen M3 muscarinic acetylchoine receptor antagonists
US20070185090A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
WO2005099706A2 (en) 2004-04-07 2005-10-27 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (en) 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
TW200606161A (en) 2004-05-28 2006-02-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006017768A2 (en) 2004-08-05 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006017767A2 (en) 2004-08-06 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2008520579A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
AP2006003746A0 (en) 2006-10-31
JP5014121B2 (ja) 2012-08-29
EP1740177B1 (en) 2012-08-08
UA95768C2 (ru) 2011-09-12
PT1740177E (pt) 2012-11-02
US20140371264A1 (en) 2014-12-18
EA021994B1 (ru) 2015-10-30
ECSP066940A (es) 2006-12-20
AU2005237576A1 (en) 2005-11-10
UY28871A1 (es) 2005-11-30
EP1740177A4 (en) 2010-05-05
KR101037026B1 (ko) 2011-05-25
SI2570128T1 (sl) 2016-11-30
SG186597A1 (en) 2013-01-30
US9045469B2 (en) 2015-06-02
US20090124653A1 (en) 2009-05-14
CA2564742C (en) 2012-01-10
PL2570128T3 (pl) 2017-09-29
BRPI0510170B8 (pt) 2021-05-25
EA201100019A1 (ru) 2011-12-30
FR14C0075I2 (fr) 2015-05-22
LU92565I9 (cg-RX-API-DMAC10.html) 2019-01-17
IL178152A0 (en) 2006-12-31
EP3111936A1 (en) 2017-01-04
AP2213A (en) 2011-03-01
BE2014C063I2 (cg-RX-API-DMAC10.html) 2024-08-08
FR14C0075I1 (fr) 2014-11-21
WO2005104745A3 (en) 2006-08-03
DK1740177T3 (da) 2012-10-29
NL300694I2 (cg-RX-API-DMAC10.html) 2015-12-29
SI1740177T1 (sl) 2012-12-31
CY2014043I2 (el) 2015-12-09
CY1118082T1 (el) 2017-06-28
TW200605887A (en) 2006-02-16
ES2600405T3 (es) 2017-02-08
EA015033B1 (ru) 2011-04-29
JP2012162559A (ja) 2012-08-30
CN1976701A (zh) 2007-06-06
MA28631B1 (fr) 2007-06-01
CN102040602A (zh) 2011-05-04
WO2005104745A2 (en) 2005-11-10
DK2570128T3 (en) 2016-11-07
ES2392848T3 (es) 2012-12-14
LU92565I2 (fr) 2014-12-02
ZA200608565B (en) 2019-12-18
US7498440B2 (en) 2009-03-03
US20160002220A1 (en) 2016-01-07
HRP20120832T1 (hr) 2012-11-30
US20070185155A1 (en) 2007-08-09
NZ549997A (en) 2010-10-29
IL178152A (en) 2011-05-31
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
CY1113196T1 (el) 2015-12-09
US8575347B2 (en) 2013-11-05
JP5398871B2 (ja) 2014-01-29
US20130030015A1 (en) 2013-01-31
LT2570128T (lt) 2016-10-10
ES2392848T4 (es) 2014-10-01
NO2017018I2 (no) 2018-05-14
TWI363759B (en) 2012-05-11
US20120157491A1 (en) 2012-06-21
NO2017018I1 (no) 2017-05-04
NO2017017I1 (no) 2017-05-04
NO338959B1 (no) 2016-11-07
US7488827B2 (en) 2009-02-10
CA2755954C (en) 2014-02-18
BRPI0510170A (pt) 2007-10-02
US8853404B2 (en) 2014-10-07
CA2755954A1 (en) 2005-11-10
EP1740177A2 (en) 2007-01-10
HRP20161385T1 (hr) 2016-12-02
CA2564742A1 (en) 2005-11-10
US9144571B2 (en) 2015-09-29
KR20110010841A (ko) 2011-02-07
HK1102423A1 (en) 2007-11-23
HUE031304T2 (hu) 2017-07-28
KR20070015412A (ko) 2007-02-02
PL1740177T3 (pl) 2012-12-31
NL300694I1 (cg-RX-API-DMAC10.html) 2015-12-29
PE20060259A1 (es) 2006-03-25
NO20065417L (no) 2006-12-29
CY2014043I1 (el) 2015-12-09
US20150238470A1 (en) 2015-08-27
US8183257B2 (en) 2012-05-22
EP2570128B1 (en) 2016-08-10
US8309572B2 (en) 2012-11-13
EP2570128A1 (en) 2013-03-20
HUS1400053I1 (hu) 2017-07-28
BRPI0510170B1 (pt) 2018-12-18
KR101152032B1 (ko) 2012-06-11
JP2007534769A (ja) 2007-11-29
AR050902A1 (es) 2006-12-06
MY144753A (en) 2011-10-31
MXPA06012405A (es) 2007-01-17
AU2005237576B2 (en) 2012-01-12
EA200601991A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
ATE413400T1 (de) Cgrp-rezeptorantagonisten
DK1951660T3 (da) Histamin-3-receptorantagonister
DK1720859T3 (da) Chemokinreceptorantagonister
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
DE602004030930D1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
IS8119A (is) Þétt N-heteróhringlaga efnasambönd og notkun þeirra sem CRF viðtakamótlyfja
DK2653465T3 (da) Opioid-receptormodulatorer
NO20051871D0 (no) Opioid reseptorantagonister
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
IS8501A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
EP1765805A4 (en) CGRP RECEPTOR ANTAGONISTS
EP1871752A4 (en) ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
IL190686A0 (en) Il-21 receptor antagonists
TWI348467B (en) Nk1 antagonists
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
IL179462A0 (en) Use of the receptor gpr86
ATE534628T1 (de) Urotensin ii-rezeptorantagonisten
EP1799672A4 (en) CGRP RECEPTOR ANTAGONIST
EP1812008A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
EP1819342A4 (en) QUINOLINE tachykinin ANTAGONISTS
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf